





Oct. 12, 2022

Time (JST)	Speakers	Country	Lecture title (tentative)
16:00-18:00 (Opening Ceremony)	Plenary lecture		Hypertension: Past Progress, Present Challenges and Future Promises.
	Victor J Dzau	USA	




Oct. 13, 2022

Time (JST)	Speakers	Country	Lecture title (tentative)
7:40-8:40	Session1-2	Disaster and Environmental Hazards in Hypertension-1	
	Narsingh Verma	INDIA	Particulate matter exposure and cardiovascular disorder matter exposure and cardiovascular disorder
	Wataru Umishio	JAPAN	Association of exposure to air pollutants during adolescence with blood pressure in young adulthood
	Jingjing Wu	CHINA	Smart Wellness Housing And Blood Pressure Control
7:40-8:40	Session5-21	Hypertension and Psychoneurological/Physical Aging	
	Katsuya Iijima	JAPAN	Regional regeneration in super-aged society
	Jeff D. Williamson	USA	A review and new insights from the SPRINT MIND trial data
	Yuko Nakamura	JAPAN	Association of hypertension and dyslipidemia with cognitive function in community-dwelling older adults: the SONIC study
	Ruth Peters	AUSTRALIA	Blood pressure, antihypertensives and dementia, an individual patient data meta-analysis
7:40-8:40	Session11-48	Imaging for Hypertension Management	
	Hidekazu Tomimoto	JAPAN	Brain imaging for the management of hypertension
	Roland E Schmieder	GERMANY	Renal Imaging in Hypertension
	Yan Liu	CHINA	Associations of Brachial-Ankle Pulse Wave Velocity with Left Atrial Stiffness and Left Atrial Phasic Function in Hypertension
	Yusuke Ishiyama	JAPAN	Association between PEP/ET and Left Ventricular Ejection Fraction of Pulse Wave Measurements in Patients at High Cardiovascular Risk
8:40-9:40	Plenary lecture1		
	Masashi Yanagisawa	JAPAN	Deciphering the mystery of sleep: toward the molecular substrate for sleepiness
10:00-11:00	Featured presentation1		
	Hiroshi Ishiguro	JAPAN	Robotics and Health: Avatar technology for supporting our future society
10:00-11:30	WHO-ISH Joint Session		
10:00-11:30	Session10-42	AOBP and Conventional Office BP Measurement	
	Kei Asayama	JAPAN	Current evidence and issues on AOBP from Japan
	Martin G Myers	CANADA	Automated Office Blood Pressure in Research Versus Clinical Practice
	Qi-Fang Huang	CHINA	Central and peripheral pulsatile blood pressure components in relation to cardiovascular outcome
	Oommen John	INDIA	Validation of blood pressure devices as per 2020 WHO technical specifications: a scoping review of global literature
	Kazuomi Kario	JAPAN	Inconsistent guidelines-based control status of office, home, and ambulatory blood pressure measured by an all-in-one BP monitoring device
	Konstantinos G Kyriakoulis	GREECE	Automated detection of atrial fibrillation during routine oscillometric measurement of blood pressure: Systematic review and meta-analysis
10:00-11:30	ISH Austin Doyle Award Session		




Oct. 13, 2022

Time (JST)	Speakers	Country	Lecture title (tentative)
10:00-11:20	Session1-1	Disaster and Environmental Hazards in Hypertension-2	
	Tetsuya Ohira	JAPAN	Onset of lifestyle-related diseases after the Great East Japan Earthquake among residents in Fukushima
	Satoshi Hoshide	JAPAN	Disaster hypertension and cardiovascular disease
	Sungha Park	SOUTH KOREA	Influence of the ambient temperature on blood pressure in Asia
	Neil Poulter	UK	Environmental pollutants and blood pressure
10:00-11:30	Session12-49	Cerebrovascular diseases	
	Yuda Turana	INDONESIA	Hypertension and Stroke in Asia
	Masaki Mogi	JAPAN	Hypertension and Dementia ~learning a lesson from the SPRINT~
	Paul K Whelton	USA	Hypertension management in patients with cardiovascular disease
	Ghazi Haji	IRAQ	Hypertension Management In Atrial Fibrillation Patients In Middle East
	Kazunori Toyoda	JAPAN	Emergent blood pressure lowering with intravenous nicardipine for Japanese patients with acute intracerebral hemorrhage: an individual participant data analysis
	Lorenzo Carnevale	ITALY	Impact of anti-hypertensive therapy on cerebral functional networks and connectivity
10:00-11:30	Session9-35	Cellular Senescence and Senolysis	
	Tohru Minamino	JAPAN	Targeting senescent cells as a novel therapeutic strategy for age-associated disease
	Rhian M. Touyz	CANADA	Angiotensin, vascular aging and hypertension
	Georgina Gyarmati	USA	Discovery of neuroendothelial cells and their role in hypertension and aging
	Diana Di Iorio	CANADA	The testosterone-androgen receptor pathway is associated with carotid atherosclerotic plaque instability in men with severe carotid atherosclerosis
	Livia L Camargo	CANADA	Vascular smooth muscle cell proteome and phenotypic switching in human hypertension are Nox5-dependent
	Mei You	CHINA	Asprosin induces vascular endothelial-to-mesenchymal transition in diabetic lower extremity peripheral artery disease
	Chloe Landry	CANADA	Neutrophil extracellular traps as mediators of endothelial damage in hypertension and diabetes
10:00-11:30	Session9-38	Inter-organ Communication	
	Jens Titze	SINGAPORE	Multi-organ regulation of body fluid and blood pressure homeostasis
	Yumiko Oishi	JAPAN	Immunometabolism as a novel therapeutic target of cardiovascular diseases
	Peng Gao	CHINA	Restoration of SIRT3 expression in liver alleviates high-salt-induced hypertension
	Daniel J Fehrenbach	USA	ROCK2 Specific Inhibition Decreases Th17/Treg Balance and Reduces Hypertension and Hypertension-Associated End-Organ Damage
	Iryna Tverezovska	UKRAINE	Selenium levels and functional state of liver in patients with hypertension and nonalcoholic fatty liver disease
	Leonardo A Sechi	ITALY	Nonalcoholic fatty liver disease and arterial stiffness in treatment-naïve hypertensive patients
	Leonardo A Sechi	ITALY	Intrarenal renal resistance index and nonalcoholic fatty liver disease in untreated hypertensive patients



Oct. 13, 2022

Time (JST)	Speakers	Country	Lecture title (tentative)
11:00-11:30	ISH2022 Kyoto Chairperson's Address		
	Hiroshi Itoh	JAPAN	
13:40-15:10	ISH-ESH Joint Session	Underestimated mechanisms in onset and maintenance of hypertension	
	Nadia A. Khan	CANADA	Drugs and substances that increase blood pressure
	Wiktorija Wojciechowska	POLAND	Noise Pollution and Arterial Hypertension
	Alexandre Persu	BELGIUM	Post-traumatic stress disorder and Hypertension
	Takayoshi Ohkubo	JAPAN	Seasonal variation in blood pressure and the risk of cardiovascular diseases
13:40-15:10	Session6-24	Advancing the Drug Therapy for Hypertension	
	Dick De Zeeuw	NETHERLANDS	High blood pressure and Albuminuria, both therapeutic targets for cardiovascular disease protection?
	Apichard Sukonthasarn	THAILAND	Polypills for Hypertension Control in Asians
	Luis Miguel Ruilope	SPAIN	ROLE OF SACUBITRIL/VALSARTAN IN THE CONTROL OF BLOOD PRESSURE
	Wanpen Vongpatanasin	USA	Differential effects of MR antagonists and calcium channel blockers
	Catharina M C Mels	SOUTH AFRICA	Homoarginine and cardiovascular protection: potential therapeutic target?
	Ying-Mei Feng	CHINA	Effects of SGLT2 and GLP1-RA on CV disorders including hypertension
13:40-15:10	Session2-12	Target Blood Pressure Values	
	Gregory Y H Lip	UK	Optimal Blood Pressure and Cardiovascular Risk Management in Patients with Atrial Fibrillation
	Joseph T. Flynn	USA	What level of blood pressure is concerning in childhood?
	Kazunori Toyoda	JAPAN	Blood Pressure Targets for Secondary Prevention of Stroke
	Makiko Abe	JAPAN	Optimal blood pressure target to prevent severe hypertension in pregnancy: A systematic review and meta-analysis
	Sverre Erik Kjeldsen	NORWAY	Can Achieved Average Systolic Blood Pressure Below 130 mmHg Cause Harm in Elderly Hypertensive Patients with Left Ventricular Hypertrophy?
	Ahmed Arafa	JAPAN	The association between blood pressure per the 2019 JSH and 2017 ACC/AHA guidelines and heart failure risk: the Suita Study
13:40-15:10	Session11-47	Examination of Vascular Function	
	Thomas Weber	AUSTRIA	Aortic pulse wave velocity and cardiovascular risk
	Hao-Min Cheng	TAIWAN	Clinical implication of aortic stiffness
	Jacek Jozwiak	POLAND	Lipids and oxidative stress markers in cardiovascular diseases
	Yukihito Higashi	JAPAN	Clinical implication of FMD
	Stella S. Daskalopoulou	CANADA	Arterial Stiffness and Hemodynamic Parameters for the Early Prediction of Preeclampsia: a Prospective Cohort Study



Oct. 13, 2022

Time (JST)	Speakers	Country	Lecture title (tentative)
13:40-15:10	ISH-JSH team-based medicine /CME Committee Joint Session		Exercise guidance for elderly hypertensives : new perspective for disability prevention
	Hayden Barry Bosworth	USA	The hypertension team: The role of the pharmacist,nurse, and teamwork in hypertension therapy.
	Shigeru Makita	JAPAN	Reduction in cardiovascular morbidity and mortality by cardiac rehabilitation: what's the evidence?
	Henner Hanssen	SWITZERLAND	Exercise in the prevention and treatment of hypertension and associated cardiovascular risk
13:40-15:10	Women in Hypertension Research - Maximisin		
13:40-15:10	Session9-34	Bridging the Gap between Basic Science and Clinical Practice in Hypertension	
	Giuseppe Mancia	ITALY	Past and future of hypertension research
	Thomas Unger	NETHERLANDS	The Renin Angiotensin System in Basic and Clinical Research
	Jithin Kuriakose	UNITED KINGDOM	ENHANCING MAS1:ETBR INTERACTION AS A POTENTIAL VASOPROTECTIVE STRATEGY IN STROKE-PRONE SHR
	Ivana Vaněčková	CZECH REPUBLIC	Beneficial effects of empagliflozin on metabolic parameters and diastolic function in spontaneously hypertensive rats fed a high-fat diet
	Charles Duncan Smart	USA	CITE-seq identifies Trem2-dependent gene program driving cardiac remodeling in a hypertensive model of heart failure with preserved ejection fraction
	Zuzana Honetschlägerová	CZECH REPUBLIC	Impairment of renal blood flow autoregulation and pressure-natriuresis: role in the development of heart failure in Ren-2 transgenic hypertensive rats
	Asadur Md Rahman	JAPAN	Cardioprotective effects of finerenone associated with the suppression of myocardial sodium accumulation in aldosterone-induced rats
13:40-15:10	Session6-23	Adrenal Pathology and Hypertension	
	Alessandro Prete	UK	Management of adrenal incidentalomas
	Hironobu Sasano	JAPAN	Pathology update of Cushing's syndrome and primary aldosteronism according to WHO 2022
	Michael Stowasser	AUSTRALIA	Updates on familial hyperaldosteronism
	Akiyo Tanabe	JAPAN	Recent advances in the management of pheochromocytoma and paraganglioma
	Hiroki Shimada	JAPAN	An approach to identify the undetermined adipocyte-derived factor(s) that stimulate aldosterone synthase gene (CYP11B2) expression
	Dong Yoon Lim	SOUTH KOREA	Inhibitory Impacts of Chlorogenic Acid on Adrenal Catecholamine Secretion
15:30-17:00	Session6-23	Guidelines for the Management of Hypertension	
	Yook-Chin Chia	MALAYSIA	Similarities and differences between international and asian guidelines for the management of high blood pressure
	Naoyuki Hasebe	JAPAN	Amelioration of discrepancy between physicians and patients in hypertension management (tentative)
	Paolo Verdecchia	ITALY	Which is the optimal BP target to achieve? Should Guidelines be updated?
	Agustin J. Ramirez	ARGENTINA	Viewpoint on Guidelines for Management of Hypertension in Latin America
	Nobuhito Hirawa	JAPAN	JSH Guideline for the management of hypertension 2019 (JSH2019) ~ Concept and subsequent challenges ~




Oct. 13, 2022

Time (JST)	Speakers	Country	Lecture title (tentative)
15:30-17:00	Session8-32		How to Achieve Hypertension Zero in Community?
	Katsuyuki Miura	JAPAN	Epidemiology and control of hypertension in Japan
	Keith C. Ferdinand	USA	Community-Based Approaches to Prevention and Management of Hypertension
	Mitsuru Ohishi	JAPAN	Efforts aimed to achieve hypertension zero in community; experience in Makurazaki city
	Ruan Kruger	SOUTH AFRICA	Gaps and advances for the prevention of hypertension in Africa: Insights from the ExAMIN Youth SA study
	Aletta E. Schutte	AUSTRALIA	Cost-effectiveness of a full scope of pharmacist care for hypertension in Australia
15:30-17:00	Session6-28		Resistant Hypertension
	Cheryl Carcel	AUSTRALIA	Resistant hypertension: clinical characteristics and blood pressure control
	Atsuhiko Ichihara	JAPAN	Clinical management of mineralocorticoid receptor-associated hypertension
	Andrzej Januszewicz	POLAND	Causes and management of renovascular hypertension
	Masashi Mukoyama	JAPAN	Natriuretic peptides and humoral factors in cardiorenal syndrome and resistant hypertension
	Jean-Jacques Mourad	FRANCE	Antihypertensive treatment prescribing behaviours in French general practice in 2021
	James Hui	USA	Pharmacokinetics, pharmacodynamics, and safety results from a phase 1 multiple ascending dose study of the selective aldosterone synthase inhibitor CIN-107
15:30-17:00	Session12-51		DM and Metabolic Syndrome
	Claudio Borghi		Uric Acid and cardiovascular diseases
	Michio Shimabukuro	JAPAN	Cluster analysis of diabetes and hypertension
	Laura Savare	ITALY	Antidiabetic drug therapy and survival in elderly frail patients. Real-life evidence from Italy
	Shota Ikeda	JAPAN	Effectiveness of statin intensive therapy in type 2 diabetes with high visit-to-visit blood pressure variability
	Haruhito Uchida	JAPAN	EFFECT OF MINERALOCORTICOID RECEPTOR BLOCKER, ESAXERENONE, ON HOME BLOOD PRESSURE AND ALBUMINURIA IN JAPANESE HYPERTENSIVE PATIENTS WITH DKD (EV-DKD Study)
	Atsushi Tanaka	JAPAN	SGLT2 Inhibition on Vascular Function and Atherosclerosis: Cleared or Yet?
15:30-17:00	ISH-JSH New Investigator Committee Joint Ses		
15:30-17:00	Session9-36		Vascular Biology and Hypertension
	Theodore Kurtz	USA	The Usual Hemodynamic Mechanism Causing Salt-Induced Hypertension: Abnormally Increased Cardiac Output or Vascular Resistance?
	Adam Greenstein	UK	Hypertension as the driver of cerebral small vessel disease and dementia
	Wakako Kawarazaki	JAPAN	Salt and age-related hypertension
	Yu Zhao	CHINA	SGLT2 inhibitor canagliflozin antagonizes salt-sensitive hypertension through modifying TRPC3 mediated vascular calcium handling
	Augusto Montezano	CANADA	ACE2 is involved in SARS-CoV-2 induced endothelial cell inflammation independent of viral replication
	Anmin Ren	CHINA	Endothelial GATA5 positively regulates angiogenesis via cathepsin S-mediated Angpt2/Fik1 and MMP2/9 signaling pathways




Oct. 13, 2022

Time (JST)	Speakers	Country	Lecture title (tentative)
15:30-17:00	Session9-36	New Devices, Vaccines, and Cell Therapy for Hypertension	
	Hironori Nakagami	JAPAN	Therapeutic Vaccine for chronic diseases
	Dylan Burger	CANADA	Extracellular vesicles: Biomarkers and Beyond
	Jan Danser	NETHERLANDS	Angiotensinogen siRNA for hypertensive patients
	Brandi Wynne	USA	Refurbishing Old Targets for New Hypertension Treatments
	Xin Fan	CHINA	Angiotensin II reduces the expression of Cx43 and inhibits the c-SRC /MAPK/ERK pathway via Cx43 in cardiomyocytes




Oct. 14, 2022

Time (JST)	Speakers	Country	Lecture title (tentative)
7:40-8:40	Session12-52-2	Cardiovascular disease, Heart Failure and Atrial Fibrillation-1	
	Gian Paolo Rossi	ITALY	Atrial fibrillation
	Rafael Castillo	PHILIPPINES	Hypertension and Cardiovascular Disease in Asia
	Yuya Takahashi	JAPAN	Is hypertension a cause of atrial cardiomyopathy in patients with atrial fibrillation? -Evidence from atrial biopsy-
	Yoshihiro Kokubo	JAPAN	Plasma Atrial and Brain Natriuretic Peptides Levels and the Risk of Incident Atrial Fibrillation: The Suita Study
7:40-8:40	Session2-10	Multidisciplinary Approach to Clinical Inertia	
	Xin-Hua Zhang	CHINA	Clinical Inertia in primary care services implementing HEARTS hypertension control project
	Yoko Inagaki	USA	May Measurement Month in Nepal: Five-year comparison of blood pressure screening results in 2017 - 2021
	Buna Bhandari Bhattarai	NEPAL	Effectiveness and acceptability of Mobile Phone Text Messaging Intervention to Improve Blood Pressure Control (TEXT4BP) among Hypertensive Patients in Nepal
	Tzung-Dau Wang	TAIWAN	Current Realities of Home Blood Pressure Monitoring from Physicians Perspectives: Results from Asia HBPM Survey 2020
	Soon Jun Hong	SOUTH KOREA	Comparison of third-dose triple versus third-dose dual antihypertensive combination therapies in patients with essential hypertension during 8-week follow-up
9:00-9:40	Plenary lecture2	Toward precision medicine of metabolic diseases based on genetic ancestry	
	Hiroo Imura	JAPAN	JAPAN




Oct. 14, 2022

Time (JST)	Speakers	Country	Lecture title (tentative)
10:00-11:30	ISH position papers and other publications (2021-2022)		
	Maciej Tomaszewski	UK	
	Hiroshi Itoh	JAPAN	
	Maciej Tomaszewski	UK	overview of the strategy and outputs (2021-22)
	Nadia A. Khan	CANADA	Virtual Management of Hypertension: ISH Position Paper
	George S Stergiou	GREECE	2: Bedtime dosing of antihypertensives
	Bryan Williams	UK	3: Combination treatment in hypertension
	Fadi J Charchar	AUSTRALIA	4: Lifestyle changes in hypertension
	Aletta E. Schutte	AUSTRALIA	Addressing global disparities in blood pressure control: Perspectives of the International Society of Hypertension
	Tazeen Jafar	SINGAPORE	Scaling-up Hypertension Care in Resource-Challenged Settings Globally
10:00-11:30	Session 13-54	Genetic and Epigenetic Regulation of Blood Pressure-1	
	Maria-Christina Zennaro	FRANCE	Genetic mechanisms of hypertension in different forms of primary aldosteronism
	Norihiro Kato	JAPAN	Genomic analyses of hypertension-associated diseases across ethnic groups and species
	Felix Vaura	FINLAND	Phenome-wide analysis of a blood pressure polygenic risk score
	Xiaoguang Xu	UNITED KINGDOM	Uncovering new genes, tissues and therapeutic targets for blood pressure through large-scale transcriptome-wide association studies
	Adrien Georges	FRANCE	Genome wide association study of fibromuscular dysplasia reveals mechanistic links with blood pressure regulation and other vascular diseases
	Huan Wang	CHINA	Screening of Primary Aldosteronism Rat Model with Cacna1d Mutation
	David Scannali	UNITED KINGDOM	Renal expression of microRNAs and their association with blood pressure regulation - insights from small RNA-sequencing of 493 human kidneys
10:00-11:20	Session 1-3	Hypertension and Occupational Health	
	Michael Bursztyn	ISRAEL	Occupational and environmental influences on hypertension
	Masanori Munakata	JAPAN	Clinical significance of work stress induced increase in blood pressure in hypertension management
	Yu-Ling Yu	BELGIUM	Two-Year Responses of Office and Ambulatory Blood Pressure to First Occupational Lead Exposure
	Zhen Hu	CHINA	Effect of a Workplace-Based Primary Prevention Intervention for cardiovascular disease on Incidence of Hypertension - A Cluster Randomized Controlled Trial
	B Anjum	INDIA	Effects of Rotating night shift on Circadian pattern of Ambulatory Blood Pressure/Heart Rate, Salivary cortisol and Sulfatoxy melatonin levels



Oct. 14, 2022

Time (JST)	Speakers	Country	Lecture title (tentative)
10:00-11:30	Session8-33	For perfect hypertension control in daily clinical practice: Japan method	
	Miho Kusaka	JAPAN	Old habits die hard. Reduced-sodium school lunches in elementary schools will create a new low-sodium eating habit in Japan
	Tomohiro Katsuya	JAPAN	Significance of the Japan medical association Database Of clinical MEDicine (J-DOME) in the treatment of hypertension in Japan
	Kazuo Kobayashi	JAPAN	Real world data in hypertension: data from Japan medical association Database Of clinical Medicine (J-DOME) study in Kanagawa
	Yuichi Yoshida	JAPAN	Impact of febuxostat on visit-to-visit blood pressure variability: Insights from the randomized PRIZE study
	Narumi Eguchi	JAPAN	Current Trend of Hypertension Practice by Specialists and Non-specialists in the Japanese Primary Care Settings - J-DOME Study
10:00-11:30	Session3-14	Preemptive medicine and life course approach in hypertension	
	Cesar Romero	USA	Pathophysiology and management of isolated diastolic hypertension
	Yukari Takemi	JAPAN	Achievements and challenges of food and nutrition education "Shokuiku": experience in Japan
	Asako Mito	JAPAN	Interconception Care for the women who suffered from Hypertensive Disorders of Pregnancy
	Albertino Damasceno	MOZAMBIQUE	Long term implication of hypertension on pregnancy.
	Eunji Kim	SOUTH KOREA	Trends in Socioeconomic Inequalities in Obesity Among Korean Adolescents: the Korea Youth Risk Behavior Web-based Survey (KYRBS) 2006 to 2020
	Nayara Azinheira Nobrega Cruz	BRAZIL	Higher urinary angiotensin converting enzyme activity is observed in Brazilian children and adolescents with dyslipidemia
	Dhashani Sivaratnam	MALAYSIA	Assessing the level of practice among primary care physicians regarding hypertensive disease of pregnancy(HDP): a cross-sectional national survey in Malaysia.
10:00-11:30	Session6-26	Denervation for High Blood Pressure Control	
	Michael Weber	USA	Lessons Learned About Hypertension from Renal Denervation Clinical Trials
	Michel Azizi	FRANCE	Ultrasound renal denervation across the hypertension spectrum
	Felix Mahfoud	GERMANY	Renal denervation in hypertension management - where do we stand?
	Markus P Schlaich	AUSTRALIA	Multi-organ denervation for cardiometabolic risk reduction
	Kazuomi Kario	JAPAN	Renal denervation in Asia: guidelines and perspectives in clinical practice



Oct. 14, 2022

Time (JST)	Speakers	Country	Lecture title (tentative)
10:00-11:30	Session9-39		Kidney and Blood Pressure
	Sadayoshi Ito	JAPAN	The roles of kidney in blood pressure elevation
	Shigeru Shibata	JAPAN	Ubiquitin proteasome system and blood pressure regulation
	Shengyu Mu	USA	Adaptive immunity regulates renal salt-retention and blood pressure
	Takahiro Ogura	JAPAN	Renal water loss-induced skin water conservation leads to high blood pressure in spontaneously hypertensive rats
	Hans-Pete Marti	NORWAY	Hypertensive nephropathy: Glomerular proteomic profiling of kidney biopsies reveals a signature of disease progression
	Yibin Huang	JAPAN	Oxidized LDL potentiates angiotensin II-induced Galphaq activation through the AT1-LOX1 receptor complex in kidney cells
	Xiao C Li	USA	Deletion of AT _{1a} Receptors in The Proximal Tubules Augments Natriuretic Response to Atrial Natriuretic Peptide via NPR/cGMP/NO Signaling
14:00-15:00	Plenary lecture3		
	Shinya Yamanaka		
15:00-15:40	Featured presentation2		Health Maintenance and Teamwork in Space
	Naoko Yamazaki	JAPAN	
15:00-16:30	Late Breaking Session		
	Peter Sever	UK	The ASCOT Legacy Cohort: The long-term effects of blood pressure and blood pressure variability on cardiovascular and renal outcomes
	George Siopis	AUSTRALIA	Comparative effectiveness and implementation of digital health interventions for people with hypertension: Systematic review and meta-analysis of randomised controlled trials
	Kazuomi Kario	JAPAN	Effect of esaxerenone on nocturnal blood pressure combined with renin-angiotensin system inhibitor or calcium channel blocker in uncontrolled hypertension
	Nana Ishimura	JAPAN	Association between Income and Progression of Chronic Kidney Disease in Japan: a nationwide cohort study
	Lebo Francina Gafane-Matemane	SOUTH AFRICA	Circulating angiotensin converting enzyme 2 activity as a cardiovascular risk marker in a young healthy population: The African-PREDICT study
	Michél Strauss-Kruger	SOUTH AFRICA	Urinary metabolomics, dietary salt intake and blood pressure: The African-PREDICT study
	Brian J. Morris	AUSTRALIA	Gene variants that neutralize mortality risk from hypertension and thereby increase lifespan
	Tom Macdonald	UK	Evening dosing or morning dosing: insights from TIME study
15:00-16:30			ISH New Investigator Oral Presentation Award Session



Oct. 14, 2022

Time (JST)	Speakers	Country	Lecture title (tentative)
15:00-16:30	Session12-52-1	Cardiovascular disease, Heart Failure and Atrial Fibrillation-2	
	Issei Komuro	JAPAN	Hypertension and heart failure: new insights
	Sverre Erik Kjeldsen	NORWAY	Medical therapy for heart failure with preserved ejection fraction
	Abiodun Adeoye	NIGERIA	Electrocardiographic Abnormalities among Newly Presenting Hypertensive Patients: Report From Cardiovascular Risk Prediction Registry
	Nicola Riccardo Pugliese	ITALY	The relationship between ventricular-arterial coupling and aerobic capacity across the cardiovascular disease continuum: focus on proximal aortic stiffness.
	Anping Cai	CHINA	Association between obese status and incident left ventricular hypertrophy differed by achieved systolic blood pressure level
	Krasimira Atanasova Hristova	BULGARIA	Early changes in left atrial strain and global ventricular function in hypertensive patients with heart failure with preserved EF
15:00-16:30	Debate Session 1	Theme 1. Does arterial stiffness add benefit to hypertension management?	
	Charalambos Vlachopoulos	GREECE	Pro: Yes arterial stiffness adds benefit to hypertension management
	Bryan Williams	UK	Con: No arterial stiffness does not add benefit to hypertension management
	Meet the Expert	How to use mineralocorticoid receptor blockers in Hypertension	
	Hiroataka Shibata	JAPAN	
	Suzanne Oparil	USA	
15:00-16:30		APSH Oral Presentation	
15:00-16:30	Session2-7	Diversity in hypertension-related diseases and life-style modification	
	Mai Kabayama	JAPAN	The importance of multidisciplinary intervention for the prevention of CVD in Japan
	Jorge Sison	PHILIPPINES	Asian management of hypertension: Current status, home BP monitoring, and specific concerns in Philippines
	Nadia A. Khan	CANADA	Ethnicity and Risk of Cardiovascular Disease
	Paula Moliterno		Dietary patterns and cardiovascular and kidney phenotypes in an Uruguayan population cohort
	Satoko Nakamura	JAPAN	Promotion of diversity and inclusion (D&I) by the Japanese Society of Hypertension (JSH): JSH Asahikawa Declaration
	Dan Wang	CHINA	Sex Differences in Impact of Cumulative Systolic Blood Pressure from Childhood to Adulthood on Albuminuria: A 30-year Prospective Cohort Study



Oct. 14, 2022

Time (JST)	Speakers	Country	Lecture title (tentative)
15:00-16:00	RAG Session: APAC	Socio-medical issues in hypertension control in Asian-Pacific countries	
	Praew Kotruchin	THAILAND	
	Yuqing Zhang	CHINA	Social ageing in Asian-Pacific region
	Yook-Chin Chia	MALAYSIA	Diabetic epidemic in in Asian-Pacific region
	Hae-Young Lee	SOUTH KOREA	Sodium-Potassium strategy in Asian-Pacific region
	Saulat Siddique	PAKISTAN	How to make Asian-Pacific Hypertension Fact Sheet (example of Korean Hypertension Fact Sheet)
	Jiguang Wang	CHINA	Toward Asian-Pacific Hypertension Fact Sheet (Panel discussion)
	Erwinanto, Sp.Jp(K)	INDONESIA	Toward Asian-Pacific Hypertension Fact Sheet (Panel discussion)
	Sheikh Mohammed Shariful Islam	AUSTRALIA	Toward Asian-Pacific Hypertension Fact Sheet (Panel discussion)
	Rafael Castillo	PHILIPPINES	Toward Asian-Pacific Hypertension Fact Sheet (Panel discussion)
16:00-17:00	RAG Session: MENA	Hypertension Challenges in Middle East and North Africa. An urgent call for action.	
	Jafar Alsaid		Hypertension Prospective and challenges in MENA region.
	Robert Najem	LEBANON	CV risk profile and lifestyle pattern in the MENA region.
	Abdulla Shehab	UAE	Hypertension management in our region. Which guidelines to follow?
16:20-18:00	Special Presentation		
	Garr Reynolds	JAPAN	Presentation Zen: The Art of Presenting with Impact
	Anna F. Dominiczak	UK	Precision Medicine
	Akira Nishiyama	JAPAN	Future hypertension research
	Weili Zhang	CHINA	Aggressive BP management in older Asian people
	Takuya Kishi	JAPAN	
16:30-18:00	ISH-JSH International Committee Joint Session		
16:30-18:00	ISH2022 Kyoto Young Investigator Award Session		
16:30-18:00	Session2-6	Global Burden of Disease (GBD) on Hypertension	
	Gladys E. Maestre	USA	GBD on hypertension and cognitive function in Americas
	Gregory A Roth	USA	Estimating the Global Burden of High Systolic Blood Pressure
	Myeong-Chan Cho	SOUTH KOREA	Current Status and Future Perspectives of Elderly Hypertension in Asia
	Sheikh Mohammed Shariful Islam	AUSTRALIA	Burden of hypertensive heart disease and high systolic blood pressure in Australia from 1990-2019: Results from the GBD study
	Narayanaswamy Venketasubramanian	SINGAPORE	STROKE BURDEN AND HYPERTENSION IN THE ASIA-PACIFIC REGION
	Leilani Basa Mercado Asis	PHILIPPINES	SOCIO-ECONOMIC IMPACT AND BURDEN OF HYPERTENSION IN THE PHILIPPINES PROJECTED IN 2050




Oct. 14, 2022

Time (JST)	Speakers	Country	Lecture title (tentative)
16:30-18:00	APSH Invited Lecture		
	Kate Denton	AUSTRALIA	Brief early life ACE inhibition to prevent development of hypertension
	APSH Presidential Lecture		
	Hiroshi Itoh	JAPAN	
	Presentation of YI Certificates and Presentation of Oral award prize		
16:30-18:00	Women in Hypertension Research - Hypertensi		
17:00-18:00	RAG Session: Africa		



Oct. 15, 2022

Time (JST)	Speakers	Country	Lecture title (tentative)
7:40-8:40	Session4-18		Digital Devices for Hypertension Therapy
	Jiguang Wang	CHINA	Hypertension therapy using web-based programming and interpretation of ambulatory blood pressure monitoring
	Anastasia Mihailidou	AUSTRALIA	Hypertension therapy using diagnostic service for ambulatory blood pressure monitoring
	Katarzyna Stolarz-Skrzypek	POLAND	Recent IDACO analysis on the risk of progression to sustained hypertension from white-coat hypertension or masked hypertension.
7:40-8:40	WHL-ISH-RTSL Joint Session		SALT INTAKE AND HYPERTENSION in the WORLD: CURRENT CHALLENGES
	Albertino Damasceno	MOZAMBIQUE	Assessing salt intake in African populations. How to obtain reliable data?
	Daniel T. Lackland	USA	Why should we worry about sodium intake, if we include a diuretic in the hypertension treatment regimen ?
	Paul K Whelton	USA	Is the current recommendation by guidelines for hypertension to keep daily sodium intake below 5 g (sodium below 2300 mg) realistic ?
	Anastase Dzudie	CAMEROON	Social and political aspects related to promoting salt reduction and healthy diets in a population. Differences among high, mid and low income countries?
7:40-8:40	ISH-KSH Joint Session		
	Fadi J Charchar	AUSTRALIA	Lifestyle changes in management of resistant hypertension
	Maciej Tomaszewski	UK	Diagnostic approach to pseudo-resistant hypertension
	Hae-Young Lee	SOUTH KOREA	Prognosis of refractory hypertension
	Jinho Shin	SOUTH KOREA	Epidemiology of resistant hypertension in Korea: The Korean ABPM registry study
7:40-8:40	Session2-11		Prevalence, Awareness, Treatment and Control of Blood Pressure in the World
	Augustine Odili	NIGERIA	Task sharing for Control of Hypertension: the Nigerian Experience
	Yuichiro Yano	JAPAN	Blood Pressure Levels in Young Adults and Cardiovascular Disease Later in Life: CARDIA Study
	Jafar Alsaïd	BAHRAIN	Blood pressure pattern among teenagers in Bahrain
	Maha Ismail Elamin	SUDAN	Evaluating the prevalence, awareness, and control of hypertension: A Community, Based Cross Sectional Study
7:40-8:40	ECCR/HBPRCA Breakfast Joint Session		
	Gian Paolo Rossi	ITALY	Primary Aldosteronism and Atrial Fibrillation
	Revathy Carnagarin	AUSTRALIA	Homocysteine and Lipoprotein (a) as a determinant of arterial stiffness and a
	Antony Vinh	AUSTRALIA	Novel Fibrogenic Cellular Drivers of Aortic Stiffening
	Andre Felipe Rodrigues	GERMANY	Neural Control of Cardiovascular Function and Erythropoiesis by the Brain RAS
9:00-10:00	Plenary lecture4		
	Richard P Lifton	USA	



Oct. 15, 2022

Time (JST)	Speakers	Country	Lecture title (tentative)
10:20-11:20	Featured presentation3		Research on <i>Complete Nutrition Meal</i> to Avoid the Metabolic Domino Effect, Realizing Mibyou Prevention (Disease-Free State)
	Noritaka Ando	JAPAN	
10:20-11:50	Session2-8		Epidemiology of Hypertension and Cardiometabolic Disorders
	Yan Li	CHINA	Central hypertension is a non-negligible cardiovascular risk factor
	Tazeen Jafar	SINGAPORE	Trends in Hypertension in Singapore and Evidence-Based Solutions
	Huynh Van Minh	VIETNAM	Hypertension and some related risk factors from May Measurement Month screening programme in Vietnam from 2017 to 2019.
	Shigeyuki Saito	JAPAN	Perspectives from longitudinal cohort study in northern Japan - Hypertension, metabolic disorders and cardiovascular disease-
	Mai Kabayama	JAPAN	The health awareness and spillover effects of a community intervention by home blood pressure measurement: Nose Study
10:20-11:50	Session6-29		Sleep Apnea and Severe Hypertension
	Elizabeth Muxfeldt	BRAZIL	Sleep Apnea and Refractory Hypertension
	Kunihiro Matsushita	USA	Obstructive Sleep Apnea and Risk of CKD: findings from the Atherosclerosis Risk in Communities Study
	Federico Rea	ITALY	The impact of renal denervation procedure on the use of antihypertensive drugs. A real-life investigation from Italy
	Sebastien Rubin	FRANCE	HAMA, an European Registry of Malignant Hypertension supported by the European Society of Hypertension: preliminary results and current perspectives
	Ayako Kokubo(Urabe)	JAPAN	Peak of Nocturnal Blood Pressure Surge in Seconds is Associated with Left Ventricular Mass Index in Obstructive Sleep Apnea Patients
	Nanfang Li	CHINA	Higher Plasma Aldosterone Concentrations Are Associated With Elevated Risk of Aortic Dissection and Aneurysm: a Case-Control Study
	Kazuomi Kario	JAPAN	Long-term Reduction in Morning and Nighttime Blood Pressure after Renal Denervation: 36-Month Results from SPYRAL HTN-ON MED Pilot Trial
10:20-11:50	Debate Session 2		Theme 1. Should we start antihypertensive treatment with combination therapy?
	Alexandre Persu	BELGIUM	Starting antihypertensive treatment with combination therapy- Pro.
	Jan A Staessen	BELGIUM	Starting Antihypertensive Treatment with Combination Therapy: Con Side of the Argument
			Theme 2. Should we stop antihypertensive medications for the end-of-life patients with hypertension?
	Athanase Benetos	FRANCE	Pro: Yes we should stop antihypertensive medications
	Hiromi Rakugi	JAPAN	No, we should not stop antihypertensive medications for end-of-life patients with hypertension.



Oct. 15, 2022

Time (JST)	Speakers	Country	Lecture title (tentative)
10:20-11:20	Communications Committee Session		Controversies in Academia Mini-Debates
	Anastasia Mihailidou	AUSTRALIA	Topic1-Social media activity should be incorporated into performance reviews
	Erika Jones	SOUTH AFRICA	Topic1-Social media activity should be incorporated into performance reviews
	Dylan Burger	CANADA	Topic2-Publishing of work through pre-prints should become standard practice
	Swapnil Hiremath		Topic2-Publishing of work through pre-prints should become standard practice
10:20-11:50	Session5-22		Team Approach for Healthy Aged Society
	Motohiko Miyachi	JAPAN	Type of exercise and arterial stiffness
	Jorge Polonia	PORTUGAL	Social framework to promote salt reduction and healthy diets within hypertension and stroke prevention
	Lyne Cloutier	CANADA	Nurses contribution to hypertension
	Yusuke Ohya	JAPAN	Strategy of Health Promotion for Health and Longevity in Okinawa
	Lawrence J. Appel	USA	Team-based care to diagnose, treat and control hypertension: Findings from Resolve to Save Lives (RTSL)
14:00-15:30	Session10-43		Conventional and Future BP Measurement
	Chen-Huan Chen	TAIWAN	Prognostic Utility of Morning Blood Pressure Surge
	James E Sharman	AUSTRALIA	How to check whether a blood pressure device has been properly validated for accuracy
	Aletta E. Schutte	AUSTRALIA	The promise of cuffless blood pressure monitoring in managing hypertension
	Jianfeng Huang	CHINA	Circadian rhythm of peripheral and central arterial blood pressures in relation to all-cause mortality
	Keisuke Narita	JAPAN	Nighttime and Daytime Home Blood Pressure and the Cardiovascular Disease Incidence in Treatment-Resistant Hypertension
	Audrey Adji	AUSTRALIA	TRANSCATHETER AORTIC VALVE REPLACEMENT DOES NOT RESULT IN SUSTAINED LOAD TRANSFER WITH INCREASED VASCULAR LOAD



Oct. 15, 2022

Time (JST)	Speakers	Country	Lecture title (tentative)
14:00-16:20	Session13-55/56	Genetics, Epigenetics, and microRNAs in cardiovascular diseases	
	Toshiro Fujita	Japan	Epigenetic mechanism of salt-sensitive hypertension
	Stephen Harrap	Australia	Prevention of experimental genetic hypertension - genomic clues from the kidney.
	Chao LI	CHINA	Long noncoding RNA p21 alleviates endothelial progenitor cells damage and promotes endothelial repair in hypertension through enhancing autophagy
	Akihito Hishikawa	JAPAN	Association between DNA methylation age or DNA damage in urinary shedding cells and early CKD
	Qiu Jing Cai	CHINA	Identification of Ferroptosis-Related Genes in Carotid Atherosclerosis on Bioinformatic Analysis
	Amarsanaa Javkhant	JAPAN	Dysfunction of ATP2B1, one of hypertension associated genes, in CD4+ T cells induce colitis through the CD4+ T-cell dysregulation
	Ran Nakamichi	JAPAN	Continuous non-mutagenic DNA damage in podocytes activates pathogenic memory T cells through altered DNA methylation
	Junyi Yu	CHINA	LncRNA PSR Regulates Vascular Remodeling through Encoding a Novel Protein Arteridin
	Kaori Hayashi	Japan	DNA damage repair and DNA methylation in the kidney and CKD
	Fadi J Charchar	Australia	Non-coding RNA and microRNA in cardiovascular diseases
14:00-16:30	› Best Oral Presentation Award Session		
14:00-15:30	Session	HOPE Asia Joint Session	
	Yook-Chin Chia	MALAYSIA	Comparison of Ethnic Differences of Knowledge, attitudes and practice of salt intake and blood pressure level Malaysia
	Yuda Turana	INDONESIA	Blood Pressure Variability and Neurodegenerative Diseases
	Teo Boon Wee	SINGAPORE	Telemedicine in Hypertension
	Narsingh Verma	INDIA	Adolescent hypertension in Asia
14:00-15:30	Session7-30	COVID-19 and Hypertension- Myths and Facts	
	Koichi Tamura	JAPAN	Hypertension and COVID-19 in Japan
	Hisashi Kai	JAPAN	Effects of RAS inhibitors on ACE2 expression in animal models
	Louise Burrell	AUSTRALIA	Diverse biology of human ACE2
	Francisco J Rios	UNITED KINGDOM	Endothelial inflammation and dysfunction induced by SARS-CoV-2 Spike protein 1 involve ADAM17 and Interferon activation pathways
	Tlili Barhoumi	SAUDI ARABIA	Plasma from SARS-CoV-2 Patients Induces Oxidative Stress and Endothelial Dysfunction via Angiotensin II Type 1 Receptor (AT1R)/P38 MAPK Pathway
	Intisar Abdelrahim Bashir Omer	SUDAN	Factors affecting development of Akl among covid-19 hypertensive patients



Oct. 15, 2022

Time (JST)	Speakers	Country	Lecture title (tentative)
14:00-15:30	Session9-37		Inflammation and Immunity
	Ernesto Schiffrin	CANADA	Inflammation and immunity in hypertension
	Tomasz Guzik	UK	Translating novel inflammatory mechanisms of hypertension to clinical practice - from chronic inflammatory disorders to periodontitis.
	Pierre Paradis	CANADA	Memory Gamma Delta T Cells Play a Role in Hypertension
	Pierre Paradis	CANADA	Angiotensin II-induced blood pressure elevation was potentiated together with increases in interferon-gamma producing T cells in interleukin-23 receptor-deficient mice
	Lance N Benson	USA	Role of interferon gamma in T cell mediated salt-retention in the kidney and progression of hypertension
	Xiao-Dong Li	CHINA	Activation of Cathepsin S/CXCL1 axis-mediated macrophage and tubular cell crosstalk leads to renal inflammation and fibrosis
	Ulrike Steckelings	DENMARK	Protective roles of compound 21 in organ damage
14:00-15:30	Session		RAG Session: SACA
	Mansi Patil	INDIA	Diet as a major risk factor, dietary recommendations
	Dinesh Neupane	USA	A five-year summary of the MMM campaign in Nepal
15:30-16:30	Session		Featured presentation4
	Daiko Matsuyama	JAPAN	Spirit of Kyoto, spirit of Zen
14:00-16:20	Session13-55/56		Genetic and Epigenetic mechanism of hypertension and related diseases
	Toshiro Fujita	JAPAN	Epigenetic mechanism of salt-sensitive hypertension
	Stephen Harrap	AUSTRALIA	Prevention of experimental genetic hypertension - genomic clues from the kidney.
	CHAO LI	CHINA	Long noncoding RNA p21 alleviates endothelial progenitor cells damage and promotes endothelial repair in hypertension through enhancing autophagy
	AKIHITO HISHIKAWA	JAPAN	Association between DNA methylation age or DNA damage in urinary shedding cells and early CKD
	QIUJING CAI	CHINA	Identification of Ferroptosis-Related Genes in Carotid Atherosclerosis on Bioinformatic Analysis
	AMARSANAA JAVKHLANT	JAPAN	Dysfunction of ATP2B1, one of hypertension associated genes, in CD4+ T cells induce colitis through the CD4+ T-cell dysregulation
	RAN NAKAMICHI	JAPAN	Continuous non-mutagenic DNA damage in podocytes activates pathogenic memory T cells through altered DNA methylation
	JUNYI YU	CHINA	LncRNA PSR Regulates Vascular Remodeling through Encoding a Novel Protein Arteridin
	Kaori Hayashi	JAPAN	DNA damage repair and DNA methylation in the kidney and CKD
	Fadi J Charchar	AUSTRALIA	Non-coding RNA and microRNA in cardiovascular diseases



Oct. 15, 2022

Time (JST)	Speakers	Country	Lecture title (tentative)
15:30-17:00	Session12-50		Chronic kidney disease (CKD)
	Naoki Kashihara	JAPAN	Past, present and future of CKD in Japan
	Motoko Yanagita	JAPAN	Role of tertiary lymphoid tissues in kidney inflammation
	Teo Boon Wee	SINGAPORE	Hypertension and kidney disease in Singapore
	Marcelo Orias	USA	Hypertension and kidney disease progression
	Toshihiko Ishimitsu	JAPAN	New Insights into the Optimal Antihypertensive Therapy in CKD Patients
15:30-17:00	Women in Hypertension Research - Hypertensi		
15:30-17:00	Mentorship and Training		
15:30-16:30	RAG Session: Europe		
17:00-18:30	ISH Awards Ceremony, Presidential Lecture and Franz Volhard Lecture		
	Maciej Tomaszewski	UK	



Oct. 16, 2022

Time (JST)	Speakers	Country	Lecture title (tentative)
7:30-9:00	Session7-31	Convergence of Communicable and Non-Communicable Diseases in the Post-COVID-19 Era	
	Reinhold Kreutz	GERMANY	Lifestyle, psychological, socioeconomic and environmental factors and their impact on hypertension during the COVID-19 pandemic
	Midori Yatabe	JAPAN	Telemedicine for Post-COVID-19 Management of Hypertension
	Telmo Pereira	PORTUGAL	COVID-19 and Arterial Stiffness in vaccinated young adults without prior co-morbidities: a cross-sectional analysis of the Fit@4COVID cohort study
	Alvin Kuate Defo	CANADA	HIV INFECTION AND ANTIRETROVIRAL THERAPY ARE ASSOCIATED WITH INCREASED ARTERIAL STIFFNESS: A SYSTEMATIC REVIEW AND META-ANALYSIS
	Matias G Zanuzzi	ARGENTINA	ISOLATED NOCTURNAL HYPERTENSION IN PATIENTS LIVING WITH HUMAN IMMUNODEFICIENCY VIRUS (HIV)
	Nikolay Tselov	BULGARIA	New onset hypertension and early changes in left ventricular function in post COVID -19 condition
	Shuichiro Araki	JAPAN	COVID-19 mortality correlates with chronic disease burden among countries' ongoing social development
7:30-9:00	Session3-13	Generation and life course factors in hypertension	
	Empar Lurbe	SPAIN	The changing epidemiology of hypertension in children and adolescents.
	Erika Jones	SOUTH AFRICA	Hypertension in adolescents and opportunities for intervention in South Africa
	Anne Monique Nuyt	CANADA	Preterm birth: A new risk factor for adult hypertension
	Juliana Kagura	SOUTH AFRICA	Hypertension from Childhood to Adulthood: the BT20+ Study
	Ruan Kruger	SOUTH AFRICA	Central adiposity in childhood increases the likelihood of early vascular aging
	Suttira Intapad	USA	Intrauterine growth restriction causes an alteration in kidney gene expression
	Rena Kashima	JAPAN	A prospective observation for orthostatic dysregulation and intolerance in adolescence: Study Protocol of the Suita Offspring Study
9:10-10:30	Session20-1	Healthy diet and cardio-metabolic diseases-1	
	Paul Elliott	UK	Nutrition, Cardio-metabolic Risk and the Metabolome
	Costas Tsioufis	Greece	Recent evidence on mediterranean diet and blood pressure control
	XINYUE LANG	CHINA	The association between calf circumference and mid-upper arm circumference and prevalence of hypertension: Findings from the PURE China Study
	YUKIO YAMORI	JAPAN	Urinary Biomarker Analyses on Japanese, Mediterranean and Euro-Western Populations: Which is Better for Post-pandemic Longevity?
	Takuya Tsuchihashi	Japan	Practical and personal education of dietary therapy in hypertensive patients




Oct. 16, 2022

Time (JST)	Speakers	Country	Lecture title (tentative)
7:30-8:30	WHL-ISH-Lancet Commission on Hypertension Joint session	VALIDITY OF AUTOMATED BLOOD PRESSURE MEASUREMENT DEVICES IN CLINICAL PRACTICE AND PUBLIC HEALTH. A GLOBAL NEED FOR MORE PRECISE HYPERTENSION MANAGEMENT	
	James E Sharman	AUSTRALIA	What constitutes an acceptable test of clinical validity?
	George S Stergiou	GREECE	How can clinicians and the public determine whether a device is clinically valid?
	Pedro Ordunez	USA	What is the current status regarding device clinical validity in Latin America?
	Aletta E. Schutte	AUSTRALIA	How to ensure the sale of clinically validated BP devices in low- and middle-income countries
7:30-8:30	Session12-53	Onco-Hypertension	
	Satoshi Kidoguchi	JAPAN	Onco-Hypertension : concept and future perspectives
	NIYATA HANANTA KARUNAWAN	INDONESIA	The Evaluation of Left Ventricular Geometry and Left Ventricular Ejection Fraction between Cancer Patients Before and After Chemotherapy
	KARLA BIANCA NEVES	UNITED KINGDOM	PARP inhibition ameliorates VEGF inhibitor-associated vascular dysfunction via TRPM2
	KRASIMIRA ATANASOVA HRISTOVA	BULGARIA	The effects of handgrip stress test on hemodynamic parameters in patients with hypertension and diastolic heart failure
	Wook Bum Pyun	SOUTH KOREA	Onco-hypertension; Hypertension, antihypertensives and the cancer
7:30-9:00	Session10-44	Evidence and Perspective of White-coat Hypertension and Masked Hypertension	
	Daichi Shimbo	USA	White-coat Hypertension and Masked Hypertension: Overall Evidence and Perspective from USA
	SATOSHI HOSHIDE	JAPAN	Daytime maximum ambulatory blood pressure and risk of stroke in individuals with increased ambulatory arterial stiffness index: the JAMP study
	SHIPRA BHARDWAJ	INDIA	Circadian variability of blood pressure indices during different phases of reproductive cycles in premenopausal women and their endocrinal correlation
	YAN LI	CHINA	Antihypertensive treatment in masked hypertension for target organ protection (ANTI-MASK): A randomized, double-blind, placebo-controlled trial
	TOMOYUKI KABUTOYA	JAPAN	Nondipper pulse rate pattern was associated with blood pressure variability and increase of BNP: J-HOP study
	MIO KUBO	JAPAN	The intra-week variability on home blood pressure with or without antihypertensive medication: Nose Study




Oct. 16, 2022

Time (JST)	Speakers	Country	Lecture title (tentative)
9:00-10:30	Session4-16&17	AI and Big Data Analysis in the Management of Hypertension	
	Yasushi Okuno	Japan	The Potential of AI in Hypertension Treatment
	Graeme Eisenhofer	Germany	Diagnosis of primary aldosteronism using artificial intelligence.
	Nobuyuki Kagiya	Japan	Application of AI for screening cardiovascular disease
	XUE CAO	CHINA	The burden of cardiovascular disease attributable to high systolic blood pressure across China and its provinces from 2005 to 2018
	Hyeon Chang Kim	South Korea	Current Status of Hypertension in Korea: a nationwide population-based study
	Mihoko Okada	Japan	Big Data and Real-world Data for Hypertension Management in the Era of Digital Health
9:00-10:30	Session4-15	Exercise & Sarcopenia	
	Tetsuya Takahashi	Japan	Exercise training considering the characteristics of Sarcopenia
	Fuminori Katsukawa	Japan	Energy expenditure and physical activity in life style-related diseases
	Hiroyuki Shimada	Japan	Physical activity and healthy aging
	Koichi Yamamoto	Japan	Hypertension and sarcopenia
	Rachel Climie	Australia	Vascular Ageing and Exercise
9:10-10:30	Session20-2	Healthy diet and cardio-metabolic diseases-2	
	EKAMOL TANTISATTAMO	USA	Gender Difference in the Association of Dietary Calcium Intake with Blood pressure: Analysis of the NHANES 2017 - 2020
	ALEX PEH	AUSTRALIA	Post-stroke supplementation with short-chain fatty acids accelerates recovery in mice via the G-protein coupled receptors
	HIROSHI HIROSE	JAPAN	Relations of age, visceral fat area, HOMA-R, and lifestyle habits with hypertension in the comprehensive health checkup program
	MANSI V PATIL	INDIA	Assessing the effect of simple carbohydrate restricted diet on blood pressure levels of hypertensive
	Rudy M Ortiz	USA	Caloric Restriction and Blood Pressure Regulation during Metabolic Syndrome
9:00-10:00	AHA Joint Session	Recurring secondary hypertension: not always the same cause	
	Elvira Fanelli	ITALY	
	Alexandre Persu	BELGIUM	




Oct. 16, 2022

Time (JST)	Speakers	Country	Lecture title (tentative)
9:00-10:30	Session11-46		Biomarkers for Hypertension Management
	Chiara Lanzani	ITALY	Salt sensitivity as marker for hypertension management
	Makoto Kuro-O	JAPAN	Increased fibroblast growth factor-21 in chronic kidney disease is a trade-off between survival benefit and blood pressure dysregulation
	DAN LANE	UNITED KINGDOM	UltraFast LC-MS analysis for the chemical adherence testing: sub minute run times for a panel of nine cardiometabolic medications
	DENNIS BERNIEH	UNITED KINGDOM	MICROSAMPLING BASED MASS SPECTROMETRY FOR QUANTIFICATION OF ANGIOTENSIN PEPTIDES IN THE RENIN ANGIOTENSIN ALDOSTERONE SYSTEM
	SHEILA K PATEL	AUSTRALIA	Increased plasma neurofilament light and cerebral atrophy in patients with type 2 diabetes and left ventricular hypertrophy
	Daniel Piskorz	ARGENTINA	How to Assess Beneficial Effects of Antihypertensive Treatments
9:00-10:30	Session9-41		Role of the Sympathetic Nervous System in Hypertension
	Richard Wainford	USA	Sympathetic Regulation of Salt Sensitivity
	Yoshitaka Hirooka	JAPAN	Role of the sympathetic nervous system in hypertension: Focused on the central nervous system
	SHO MATSUMOTO	JAPAN	Empagliflozin ameliorates cardiac hypertrophy and renal injury with sympathoinhibition in a rat model of hypertensive heart failure
	KENICHI KATSURADA	JAPAN	Renal denervation improves fluid retention by modulating renal SGLT2 function in rats with heart failure
	KEISUKE SHINOHARA	JAPAN	Different contribution of afferent renal nerves to development of hypertension and hypertensive heart failure in several rat models of hypertension
	Debora Simoes de Almeida Colombari	BRAZIL	Renovascular hypertension and brain: role of the renin-angiotensin system and sodium
9:00-10:00	TR		Top Rated Abstract Session
	SVERRE ERIK KJELDEN	NORWAY	Cardiovascular outcomes in hypertensive patients who discontinue study medication in a large outcome trial. The LIFE Study.
	THEODOROS KALOS	GREECE	PARAMETERS INDICATING HYPERTENSION PREVALENCE IN THREE-YEAR FOLLOW-UP STUDY OF INDIVIDUALS WITH HIGH NORMAL BLOOD PRESSURE
	KRASIMIRA ATANASOVA HRISTOVA	BULGARIA	Role of novel echocardiographic methods to detect early myocardial dysfunction in women with preeclampsia
	MASAYUKI TERAMOTO	JAPAN	Blood pressure categories and progression of common carotid artery stenosis degree in a Japanese urban population: The Suita Study
	LAURA ELIZABETH JOHANNA PEETERS	NETHERLANDS	MEASURING DRUG LEVELS USING A DRIED BLOOD SPOT COMBINED WITH PERSONALIZED FEEDBACK TO IMPROVE RESISTANT HYPERTENSION: A RANDOMIZED CONTROLLED TRIAL
	UMAR GATI ADAMU	SOUTH AFRICA	Hypertension and its Complications are common in a low Resource Specialty clinic in Nigeria




Oct. 16, 2022

Time (JST)	Speakers	Country	Lecture title (tentative)
11:10-12:40	Session1-5		SDGs and Hypertension
	Rajeev Gupta	INDIA	Socioeconomic factors and prevention of cardiovascular diseases in Asia
	Anastase Dzudie	CAMEROON	The burden of uncontrolled hypertension in Cameroon, Africa
	Yoshihiro Kokubo	JAPAN	Development of risk scores to prevent cardiovascular diseases
	CAROLINA JANSSEN	NETHERLANDS	Hypertension and its associations with multimorbidity: an analysis of 4 million participants from May Measurement Month 2017-2019
	Yasuko Bando	JAPAN	Building a monolith of cardiovascular care - the medical DX and patient well-being
	Mohammad Ishaq	PAKISTAN	Analysis of BP screening in Pakistan (MMM experience)
11:10-12:40	Session4-19		Global Effort to Promote Low-Salt, Potassium-Rich Diet
	Bruce Neal	AUSTRALIA	Effect of Salt Substitution on Cardiovascular Events and Death
	Maria Castaneda-Bueno	MEXICO	Role of the thiazide-sensitive Na ⁺ :Cl ⁻ cotransporter in the blood pressure-lowering effect of potassium rich diets.
	KIMINORI KATO	JAPAN	Prediction and prevention of the onset of hypertension from the viewpoint of estimated 24-hour salt excretion and physical fitness test
	NAOKI NAKAGAWA	JAPAN	Dietary salt intake assessed by spot urinary sodium excretion from child to adulthood in a Japanese town
	KAORI KITAOKA	JAPAN	Changes in estimated salt and potassium intake and sodium-to-potassium ratio using spot urine measurements: a 10-year follow-up of NIPPON DATA2010
	TELMO PEREIRA	PORTUGAL	Sarcocornia-based salt substitution and vascular function in healthy young adults: a randomized and controlled pilot study
	Yasuharu Tabara	JAPAN	Urinary Na/K ratio as the risk marker for essential hypertension
11:10-12:40	Session6-27		Progress and Future in Primary Aldosteronism
	John W Funder	AUSTRALIA	Primary Aldosteronism – Where to from Here?
	Adina F. Turcu	USA	Steroid Profiling in Primary Aldosteronism - From Back and White to Colors
	NAO IMAISHI	JAPAN	Mineralocorticoid Receptor Antagonists Improve Quality of Life in Patients with Primary Aldosteronism
	Elena Aisha Azizan	MALAYSIA	Histopathology-Genotype Correlation of Aldosterone- Producing Adenomas
	Kei Takase	JAPAN	CT guided and transvenous radiofrequency ablation for primary aldosteronism



Oct. 16, 2022

Time (JST)	Speakers	Country	Lecture title (tentative)
11:10-12:40	ISH-JSH Hypertension Research Editorial Committee Session	Hypertension Research up-to-date 2021. - Current topics of hypertension journals.-	
	Tatsuya Maruhashi	JAPAN	Update of vascular function
	Takahiro Masuda	JAPAN	Hypertension management in CKD: update for better cardio-renal outcomes
	Michiaki Nagai	JAPAN	Heart Disease-Focus on Left Atrium Structure-
	Kanako Bokuda	JAPAN	Preeclampsia up to date; what we should know for mother and child.
	Yoichi Nozato	JAPAN	Appropriate blood pressure assessment methods for the prevention of hypertension complications by new technologies
	Ayumi Toba	JAPAN	considering frailty and exercise for management of hypertension and hypertensive organ damage
	Keisuke Narita	JAPAN	Blood Pressure Variability; Therapeutic Target for the Prevention of Cardiovascular Disease
	Atsushi Tanaka	JAPAN	Progress of Obesity/Diabetes in Area of Hypertension Research 2021
	Yuichi Yoshida	JAPAN	A new era of progress in primary aldosteronism treatment, a new aldosterone assay, and a Clinical Practice Guideline
	Kenichi Katsurada	JAPAN	Advances in renal denervation for treating hypertension
	Masanari Kuwabara	JAPAN	Hot topics in uric acid research
	Keisuke Shinohara	JAPAN	Basic research: elucidation of "mosaic" pathogenesis of hypertension
11:10-12:40	Session6-27	Management of Hypertension Using ICT and personal health record	
	Richard McManus	UK	Clinical trials of telemonitoring to support the management of hypertension in primary care and pregnancy
	Thomas Kahan	SWEDEN	Blood pressure telemonitoring for detecting cardiovascular disorders
	MOO-YONG RHEE	SOUTH KOREA	Home blood pressure measurement for hypertension management in the real world: The importance of reporting home blood pressure to doctors
	ARISA WADA	JAPAN	Response of community residents to promotion of recommending home blood pressure measurement and factors associated with everyday-measurement:NOSE study
	UMER FAROOQ KHAN	SINGAPORE	ESTABLISHING A NEPHROLOGY-LED AMBULATORY BLOOD PRESSURE MONITORING SERVICE IN SINGAPORE
	Tzung-Dau Wang	TAIWAN	Home blood pressure survey in Southeast and East Asia



Oct. 16, 2022

Time (JST)	Speakers	Country	Lecture title (tentative)
11:10-12:40	Session9-40	The gut microbiota in blood pressure regulation	
	Francine Marques	AUSTRALIA	Guidelines for gut microbiota studies in experimental and clinical hypertension
	Ana Valdes	UK	The gut microbiome and cardiovascular risk factors in humans
	HAMDI JAMA	AUSTRALIA	GUT MICROBIAL METABOLITES LOWER 24-HOUR SYSTOLIC BLOOD PRESSURE IN HYPERTENSIVE PATIENTS
	CHUDAN XU	AUSTRALIA	The role of oral L-tyrosine, metabolised by the gut microbiota into p-Cresol derived metabolites, in blood pressure regulation
	SABRINA AHMED	JAPAN	Gut microbiome diversity and brain volume among general Japanese men
	DAVID J DURGAN	USA	Obstructive Sleep Apnea Induced Gut Dysbiosis Stimulates a Proinflammatory Response that Promotes Neuroinflammation and Hypertension
	Dominik Müller	GERMANY	How the gut microbiota regulates blood pressure: the role of the immune system
11:10-12:40	FMD	Fibromuscular Dysplasia (FMD) in Asia: a disease to (re)discover	
	Alexandre Persu	BELGIUM	The International Consensus on FMD
	Elvira Fanelli	ITALY	Asian vs. Caucasian patients in the European/International FMD Registry (FEIRI)
	Kan Zen	JAPAN	FMD in Asia: the Kyoto experience
	Jianzhong Xu	CHINA	FMD in Asia: the Shanghai experience
	Kentaro Matsubara	JAPAN	Differential diagnosis of FMD in Asia- what is different?-the Keio experience and vascular surgeons' viewpoint
	Osami Kawarada	JAPAN	Renovascular Hypertension in Japan: FMD vs. Atherosclerotic Renal Artery Stenosis
11:10-12:10		Cuffless blood pressure measurement: Has the time come?	
	Gianfranco Parati	ITALY	How could cuffless blood pressure measuring devices improve hypertension management?
	SONALI RUKSHANA GNANENTHIRAN	AUSTRALIA	Patient perspectives of a cuffless blood pressure device compared to classic out-of-clinic methods
	ISABELLA TAN	AUSTRALIA	Cuffless wearable 24-hour blood pressure monitoring versus standard ambulatory monitoring
	George S Stergiou	GREECE	Are cuffless blood pressure measuring devices ready for clinical use?